Search | Clinical Trials Finder

Conditions: Hypogonadotropic Hypogonadism
Interventions: 5-day controlled metabolic dietary intake; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 30 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Primary Hypogonadism, Hypogonadotropic Hypogonadism
Interventions: Testosterone Topical Gel, 1.62% Metered Pump, AndroGel (testosterone gel) 1.62% Metered-Dose Pump; Drug
Lead sponsor: Amneal Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Miami Gardens, Florida

Conditions: Kallmann Syndrome, Hypogonadism, Gonadal Disorder
Interventions: ketoconazole, gonadotropin releasing hormone (GnRH); Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 175 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1995 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acquired Hypogonadotropic Hypogonadism, Obesity
Interventions: Placebo, Enclomiphene; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 5
States / cities: Albany, New York • Garden City, New York • Providence, Rhode Island + 2 more

Conditions: Secondary Hypogonadism
Interventions: Androxal 25 mg; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Miami, Florida • Minneapolis, Minnesota

Conditions: Kallmann Syndrome, Hypogonadotropic Hypogonadism, GnRH Deficiency
Interventions: gonadotropin releasing hormone (GnRH); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 16 Years and older
Enrollment: 624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1989 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy Volunteers
Interventions: Leuprolide Acetate 3.75, Estradiol, Progesterone, Placebo suppository, Placebo patch; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1994 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypogonadism, Hypogonadotropic
Interventions: Clomiphene, Placebo; Drug
Lead sponsor: Sandeep Singh Dhindsa, M.D., F.A.C.E; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Secondary Hypogonadism
Interventions: 25 mg Androxal, Testim 1%; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 21 Years to 60 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: New York, New York • Purchase, New York

Conditions: Kallmann Syndrome, Idiopathic Hypogonadotropic Hypogonadism, GnRH Deficiency
Interventions: gonadotropin releasing hormone (GnRH); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypogonadotropic Hypogonadism, Kallmann Syndrome, GnRH Deficiency, PCOS, Polycystic Ovarian Syndrome, Hyperprolactinemia
Interventions: kisspeptin 112-121, GnRH; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypogonadotropic Hypogonadism
Interventions: kisspeptin 112-121, GnRH; Drug
Lead sponsor: Stephanie B. Seminara, MD; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypogonadism, Male
Interventions: Testosterone enanthate; Combination Product
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 12 Years to 17 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 20
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 17 more

Conditions: Secondary Hypogonadism
Interventions: Androxal 12.5 mg or 25 mg, AndroGel 1.62%, Placebo Capsules, Placebo Gel; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 8
States / cities: Jacksonville, Florida • Albany, New York • Raleigh, North Carolina + 5 more

Conditions: Mood Disorders, Depression
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Secondary Hypogonadism
Interventions: Androxal, AndroGel, Placebo; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 68 Years · Male only
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 18
States / cities: Birmingham, Alabama • Huntsville, Alabama • Carmichael, California + 14 more

Conditions: Primary or Secondary Hypogonadism, Constitutional Delay in Growth and Puberty (CDGP)
Interventions: Testosterone Gel (1%); Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 13 Years to 17 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 19
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 14 more

Conditions: Hypogonadotropic Hypogonadism
Interventions: kisspeptin 112-121, leuprolide acetate; Drug
Lead sponsor: Stephanie B. Seminara, MD; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Secondary Hypogonadism
Interventions: Androxal; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 68 Years · Male only
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 18
States / cities: Birmingham, Alabama • Huntsville, Alabama • Carmichael, California + 14 more

Conditions: Hypothalamic Amenorrhea, Functional, Hypothalamic Amenorrhea, Functional Hypogonadotropic Hypogonadism
Interventions: Automated Self-Administered 24-hour Dietary Assessment Tool (ASA24), REVEAL Questionnaire; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 100,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: Jacksonville, Florida • Rochester, Minnesota

Conditions: Secondary Hypogonadism
Interventions: Androxal 25 mg; Drug
Lead sponsor: Repros Therapeutics Inc.; Industry
Eligibility: 18 Years to 70 Years · Male only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hypogonadism
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 200 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Secondary Hypogonadism, Sexual Dysfunction, Erectile Dysfunction
Interventions: fispemifene, Placebo; Drug · Other
Lead sponsor: NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.); Industry
Eligibility: 18 Years to 64 Years · Male only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 16
States / cities: Little Rock, Arkansas • San Diego, California • Bradenton, Florida + 12 more

Conditions: Hypogonadotropic Hypogonadism
Interventions: Luveris® 75 IU, Luveris® 25 IU, Placebo, Recombinant human follicle stimulating hormone (r-hFSH), Recombinant human chorionic gonadotropin (r-hCG); Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Rockland, Massachusetts

Search by objective public record fields.

Low Energy Availability and Pituitary Function (LEAP Study)

Bioequivalence Study of Test and Reference Testosterone Topical Gel, 1.62% Metered Pump in Testosterone Deficient Adult Male Subjects Under Fasting Conditions

Investigating the Regulation of Reproductive Hormones in Adult Men

A Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene

Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function

Examination of Idiopathic Hypogonadotropic Hypogonadism (IHH)and Kallmann Syndrome (KS)

The Effects of Reproductive Hormones on Mood and Behavior

Hypogonadotropic Hypogonadism in Obese Young Males

To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone

Studying the Effects of 7 Days of Gonadotropin Releasing Hormone (GnRH) Treatment in Men With Hypogonadism

Kisspeptin Administration in the Adult

Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism

52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

Hormonal Causes of Menstrual-Related Mood Disorders

Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism

Observation Study of T-Gel (1%) in Treatment of Adolescent Boys With Hypogonadism

Kisspeptin Administration Subcutaneously to Patients With IHH

Study to Evaluate the Safety and Efficacy of Androxal Treatment in Men With Secondary Hypogonadism

The REgistry of Very Early Estrogen and AnovuLation

Evaluation of the Pharmacokinetics and Safety of Androxal in Male Subjects With Impaired Hepatic Function

Psychological Outcomes in Isolated GnRH Deficiency

Safety and Efficacy Study of Oral Fispemifene for the Treatment of Sexual Dysfunction in Hypogonadal Men

Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])